AI & Machine Learning

A new GenAI chatbot is replacing frustrating product manuals, earning a top award and signaling a major shift in customer experience for retail.

Dr. Frank Smith joins XenoSTART to lead its preclinical unit, aiming to leverage its vast patient-derived model library to speed up oncology drug development.

Leading crypto ATM operator Bitcoin Depot now requires ID for every transaction, a move aimed at fighting fraud but raising questions about user access.

Hyperlink InfoSystem unveils AI agents promising to slash operational costs by up to 90%, signaling a major shift in workforce and business strategy.

After a pivotal trial failure, Alector will present its new strategy at a key health conference, focusing on its innovative brain-delivery platform.

The merger, backed by private equity, creates a dominant force in higher education services, aiming to tackle digital transformation and student success.

A new voter tool uses AI to score Texas primary candidates on collaboration over conflict, aiming to reshape how voters choose their representatives.

Lithium developer Stardust Power partners with a Pentagon-aligned group, a critical move to reduce foreign reliance and fuel the U.S. energy transition.

Leaving the volatile crypto world behind, Cipher Digital is raising billions to build massive data centers for tech giants like AWS and Google.

Larimar Therapeutics' nomlabofusp receives Breakthrough Therapy Designation, paving an accelerated path for a potential disease-modifying treatment.

The bioprocessing leader posted robust 2025 earnings, outperforming the market with strategic innovation and a major expansion into Asian markets.

New data on MCO-010 gene therapy identifies ideal patients for Retinitis Pigmentosa, a key step as the one-time injection advances toward FDA approval.

The partnership moves beyond compliance, integrating deep binary analysis with lifecycle management to provide continuous software risk intelligence for critical industries.

Target Hospitality is rapidly expanding workforce housing for AI data centers, revealing the massive, unseen physical infrastructure powering the tech revolution.

Cullinan Therapeutics heads to key investor conferences, ready to showcase its T-cell engager platform for both cancer and challenging autoimmune diseases.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

With no approved therapies for Hepatitis E, Atea Pharmaceuticals' new drug shows potent preclinical results, offering a potential lifeline for vulnerable patients.

Blueprint Capital Advisors' new list of 'Active Icons' honors industry giants not just for wealth, but for their commitment to shaping a more inclusive future.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.